Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

NCT06760260 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Human Derived anti-CI135 CAR-T Injection

Sponsor

Hrain Biotechnology Co., Ltd.

Collaborators

[object Object]